CN117451865A - 金藤清痹颗粒指纹图谱的建立方法 - Google Patents
金藤清痹颗粒指纹图谱的建立方法 Download PDFInfo
- Publication number
- CN117451865A CN117451865A CN202311024413.9A CN202311024413A CN117451865A CN 117451865 A CN117451865 A CN 117451865A CN 202311024413 A CN202311024413 A CN 202311024413A CN 117451865 A CN117451865 A CN 117451865A
- Authority
- CN
- China
- Prior art keywords
- peak
- tengqing
- jin
- arthralgia
- fingerprint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 50
- 239000008187 granular material Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000001228 spectrum Methods 0.000 title claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000012488 sample solution Substances 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 14
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 12
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 12
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 12
- 229940074393 chlorogenic acid Drugs 0.000 claims description 12
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 12
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 12
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 12
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 9
- 230000014759 maintenance of location Effects 0.000 claims description 8
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 claims description 7
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 claims description 7
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 229930002966 sinomenine Natural products 0.000 claims description 7
- 239000012085 test solution Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims description 5
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 claims description 5
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 claims description 5
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 claims description 5
- 239000004378 Glycyrrhizin Substances 0.000 claims description 5
- KVRQGMOSZKPBNS-FMHLWDFHSA-N Harpagoside Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)\C=C\C=1C=CC=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KVRQGMOSZKPBNS-FMHLWDFHSA-N 0.000 claims description 5
- KVRQGMOSZKPBNS-BYYMOQGZSA-N Harpagoside Natural products C[C@@]1(C[C@@H](O)[C@@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)C=Cc4ccccc4 KVRQGMOSZKPBNS-BYYMOQGZSA-N 0.000 claims description 5
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims description 5
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 5
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 claims description 5
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims description 5
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 230000001502 supplementing effect Effects 0.000 claims description 4
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 241000258920 Chilopoda Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical group N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000031023 Amana edulis Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000766380 Iphigenia Species 0.000 description 1
- 240000001659 Oldenlandia diffusa Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001250596 Pleione Species 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000010011 qingbi Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8686—Fingerprinting, e.g. without prior knowledge of the sample components
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种金藤清痹颗粒HPLC指纹图谱的建立方法,该方法包括供试品溶液的制备、HPLC色谱条件的确定及HPLC标准指纹图谱的制作。本发明同时公开了由该方法得到的金藤清痹颗粒HPLC标准指纹图谱,该指纹图谱有35个共有峰。本发明质量检测方法操作简便、稳定性高、重现性好,所得图谱特征峰多,通过标准指纹图谱共有峰的比对,可对金藤清痹颗粒的质量进行全面评价和控制,有利于精准评估制剂的内在质量,确保临床用药的安全性、有效性。
Description
技术领域
本发明公开了一种金藤清痹颗粒HPLC指纹图谱的建立方法,属于中药制剂分析领域。
背景技术
“金藤清痹颗粒(国药准字Z20123065,鲁南厚普制药有限公司生产)”由金银花、青风藤、白花蛇舌草、玄参、地黄、山慈菇、鹿衔草、甘草、当归、白芍、蜈蚣11味中药制备而成,主要功效为清热解毒,活血消肿,通痹止痛。用于类风湿性关节炎活动期,属于毒热内蕴,湿热阻络证。症见关节肿胀,疼痛拒按,晨僵,触之发热,或皮肤发红,身热,汗多,口渴,便干溲黄,舌质红,苔黄腻,脉滑数。
金藤清痹颗粒全方以金银花、青风藤为君药;白花蛇舌草、玄参、地黄、山慈菇、鹿衔草为臣药;白芍、蜈蚣、甘草为佐药;诸药相配,具有清热解毒、活血消肿、通痹止痛之功效。金银花富含挥发油,还含有黄酮类及有机酸等,实验研究结果发现,其水煎液、口服液和注射液均具有解热、抗炎、调节机体的免疫功能等作用。青风藤主要含有青藤碱、木兰花碱等药效成分,具有抗炎镇痛、抗风湿及免疫抑制等作用,为治疗类风湿关节炎的常用中药。当归、白芍、白花蛇舌草、鹿衔草补血活血、缓急止痛、强筋健骨;玄参、干地黄、甘草、山慈菇滋阴凉血、泻火解毒;蜈蚣活血消瘀、攻毒散结、通络止痛,药理学研究表明蜈蚣能改善微循环,并有较强镇痛、抗炎的作用。诸药同用,共奏清热解毒、活血消瘀散肿、通络通痹止痛之功。
金藤清痹颗粒是中药复方制剂,含多味中药且化学成分复杂,对其进行全面有效的质量控制是保证临床疗效的重要基础。目前,关于金藤清痹颗粒的质量控制鲜有报道,且为对药材的单一成分定量分析和对部分组方药材的定性鉴别,其药效成分尚不明确,缺乏有关金藤清痹颗粒更为综合、全面的质量控制研究。为稳定和保证产品质量,需要对其质量检测和控制法进行全面地研究。中药指纹图谱作为一种中药质量控制技术及方法,具有整体性、模糊性特点,能较为全面地反应中药的整体质量。目前国内外尚没有以中药指纹图谱控制金藤清痹颗粒质量的相关专利公开及文献报道。
本发明公开了一种金藤清痹颗粒HPLC指纹图谱的建立方法,以及用该方法制作的金藤清痹颗粒HPLC标准指纹图谱,可有效反映金藤清痹颗粒化学成分的整体性和复杂性,对制剂质量进行全面地评价和控制,进而保证临床用药的安全性与有效性。
发明内容
针对现有金藤清痹颗粒质量检测方法的不足,本发明的目的是提供一种金藤清痹颗粒指纹图谱建立方法。具体来说,该方法将金藤清痹颗粒制备成供试品溶液,经过HPLC分离检测,从而获得金藤清痹颗粒HPLC标准指纹图谱,实现全方位多方面检测,完善其质量检测体系,进而为金藤清痹颗粒的真伪鉴别和内在质量提供可靠依据。
本发明为一种金藤清痹颗粒HPLC指纹图谱的建立方法,包括下列步骤:
1)供试品溶液的制备:取金藤清痹颗粒样品,研细,称取适量,置于具塞锥形瓶中,加入50%-90%甲醇,称定重量,超声提取20-50min,放冷至室温,用50%-90%甲醇补足减失的重量,摇匀,滤过,取续滤液,作为供试品溶液;
2)HPLC色谱条件的确定:Waters Xselect CSH C18柱,以乙腈-甲醇为流动相A、以0.05%-0.15%的甲酸水(V/V)为流动相B,梯度洗脱;
所述梯度洗脱条件为:
时间(min) | 流速(ml/min) | 流动相A(%) | 流动相B(%) |
0-13 | 0.7 | 5% | 95% |
13-26 | 0.7-0.9 | 5%→15% | 95%→85% |
26-45 | 0.9 | 15%→20% | 85%→80% |
45-75 | 0.9-1.0 | 20%→29% | 80%→71% |
75-85 | 1.0 | 29%→40% | 71%→60% |
85-100 | 1.0 | 40%→55% | 60%→45% |
100-115 | 1.0 | 55%→80% | 45%→20% |
115-117 | 1.0-0.7 | 80%→5% | 20%→95% |
117-122 | 0.7 | 5% | 95% |
3)指纹图谱的制作:按步骤2)色谱条件对金藤清痹颗粒供试品溶液进行分析比较,得到由样品共有特征峰构成的金藤清痹颗粒HPLC标准指纹图谱。
优选地,步骤1)所述供试品溶液的制备:取金藤清痹颗粒样品,研细,称取适量,置于具塞锥形瓶中,加70%甲醇适量,称定重量,超声提取30min,放冷至室温,用70%甲醇补足减失的重量,摇匀,滤过,取续滤液,得供试品溶液。
进一步优选地,步骤1)所述供试品溶液的制备:取金藤清痹颗粒样品,研细,称取约2g,精密称定,置具塞锥形瓶中,精密加入70%甲醇25mL,称定重量,超声提取30min,放冷至室温,用70%甲醇补足减失的重量,摇匀,滤过,取续滤液,得供试品溶液。
优选地,步骤2)所述流动相A为乙腈-甲醇(1:1),流动相B为0.1%甲酸水(V/V)。
优选地,步骤2)所述色谱柱的规格为4.6×150mm,2.5μm。
本发明中,步骤2)所述色谱条件中,检测波长:263nm;柱温:25℃;进样量:5μL
优选地,取金藤清痹颗粒待检样品,按步骤1)制备供试品溶液,步骤2)进行HPLC色谱分析,步骤3)制作标准指纹图谱。
所述金藤清痹颗粒HPLC标准指纹图谱,采用《中药色谱指纹图谱相似度评价系统2012版》软件进行相似度评价。
本发明还提供了由上述方法得到的金藤清痹颗粒HPLC标准指纹图谱,具体步骤是将15批金藤清痹颗粒样品,按上述方法制备成供试品溶液,以HPLC分离检测,使用国家药典委员会推荐的《中药色谱指纹图谱相似度评价系统2012版》软件分析,得到金藤清痹颗粒HPLC标准指纹图谱。
本发明中,所述金藤清痹颗粒HPLC标准指纹图谱有35个共有峰,以绿原酸为参照峰,其共有峰的相对保留时间tR依次分别为:0.048,0.050,0.052,0.068,0.080,0.089,0.095,0.106,0.111,0.115,0.164,0.183,0.221,0.292,0.378,0.739,0.757,0.805,0.840,0.874,0.935,0.965,1.000,1.083,1.203,1.506,1.573,1.635,1.816,1.987,2.026,2.277,2.496,2.928,3.068。
通过对照品比对,其中15号峰为青藤碱,16号峰为木兰花碱,17号峰为新绿原酸,21号峰为隐绿原酸,23号峰为绿原酸,26号峰为甘草苷,30号峰为异绿原酸B,32号峰为异绿原酸C,33号峰为哈巴俄苷,34号峰为藁本内酯,35号峰为甘草酸铵。
与现有技术相比,本发明的技术方案取得了以下有益技术效果:
1)本发明金藤清痹颗粒HPLC指纹图谱的建立方法克服现有技术检测指标单一、不能反映内在质量的缺点,所提供的金藤清痹颗粒HPLC指纹图谱建立方法精密度高、重现性好,通过对比所得指纹图谱中共有峰的有无及相似程度,可对金藤清痹颗粒的质量进行全面评价,有效地保证了成品的质量。
2)本发明根据金藤清痹颗粒的处方成分构成特点,优选最佳流动相组成及其梯度洗脱程序、流速、检测波长等,解决了特征峰难以分开及杂质峰干扰大的难题,所得指纹图谱分离度高、峰形好,各特征色谱峰均实现了良好的基线分离,稳定性好、特征峰多,能全面、准确地评价制剂的内在质量,适用于对金藤清痹颗粒产品质量的控制。
附图说明
图1为金藤清痹颗粒HPLC标准指纹图谱(1-35为35个共有峰);
图2为金藤清痹颗粒HPLC混合对照图谱;
其中15号峰为青藤碱,16号峰为木兰花碱,17号峰为新绿原酸,21号峰为隐绿原酸,23号峰为绿原酸,26号峰为甘草苷,30号峰为异绿原酸B,32号峰为异绿原酸C,33号峰为哈巴俄苷,34号峰为藁本内酯,35号峰为甘草酸铵。
图3是金藤清痹颗粒HPLC空白图谱。
图4为15批金藤清痹颗粒的HPLC指纹图谱叠加图。
具体实施方式
为了使本申请的目的、技术方案和优点更加清楚、明晰,以下将结合附图对实施例中的技术方案进行清楚、完整的描述。显而易见,以下实施例是本申请实施例的一部分,而不是全部。因此,以下对实施例的详细描述并非限定本申请要求保护的范围,本领域普通技术人员在没有作出创造性劳动的前提下所作出的等同替换或修改,均应包含在本发明的保护范围之内。
实施例1金藤清痹颗粒HPLC标准指纹图谱的建立
1仪器与试药
1.1仪器
WatersArc超高效液相色谱仪(Waters公司),Waters 2489UV/Vis检测器(Waters公司);鼎泰恒胜JY-15型超声波清洗机(鼎泰(湖北)生化科技设备制造有限公司)。
1.2试药
15批金藤清痹颗粒由鲁南厚普制药有限公司提供(批号见表1),乙腈、甲醇为色谱纯,水为重蒸馏水,其余试剂均为分析纯。
表1 15批金藤清痹颗粒批号
2方法与结果
2.1供试品溶液的制备:取金藤清痹颗粒,研细,取约2g,精密称定,置于具塞锥形瓶中,精密加入70%甲醇25mL,超声提取30min,放冷至室温,用70%甲醇补足减失的重量,摇匀,滤过,取续滤液,作为供试品溶液。
2.2对照品溶液的制备:精密称取青藤碱、木兰花碱、新绿原酸、隐绿原酸、绿原酸、甘草苷、异绿原酸B、异绿原酸C、哈巴俄苷、藁本内酯、甘草酸铵混合对照品,用70%甲醇溶解后,作为混合对照品溶液。
2.3色谱条件:色谱柱:Waters Xselect CSH C18柱(4.6×150mm,2.5μm);流动相:以乙腈-甲醇(1:1)为流动相A,以0.1%甲酸水(V/V)溶液为流动相B,按下表进行梯度洗脱:
时间(min) | 流速(ml/min) | 流动相A(%) | 流动相B(%) |
0-13 | 0.7 | 5% | 95% |
13-26 | 0.7-0.9 | 5%→15% | 95%→85% |
26-45 | 0.9 | 15%→20% | 85%→80% |
45-75 | 0.9-1.0 | 20%→29% | 80%→71% |
75-85 | 1.0 | 29%→40% | 71%→60% |
85-100 | 1.0 | 40%→55% | 60%→45% |
100-115 | 1.0 | 55%→80% | 45%→20% |
115-117 | 1.0-0.7 | 80%→5% | 20%→95% |
117-122 | 0.7 | 5% | 95% |
检测波长:263nm;柱温:25℃;进样量:5μL。
2.4指纹图谱的建立
测定15批号金藤清痹颗粒HPLC指纹图谱,并进行分析比较,得到由其共有特征峰构成的金藤清痹颗粒HPLC标准指纹图谱(参见附图1、3),其中以绿原酸为参照峰,其共有峰的相对保留时间tR依次分别为:0.048,0.050,0.052,0.068,0.080,0.089,0.095,0.106,0.111,0.115,0.164,0.183,0.221,0.292,0.378,0.739,0.757,0.805,0.840,0.874,0.935,0.965,1.000,1.083,1.203,1.506,1.573,1.635,1.816,1.987,2.026,2.277,2.496,2.928,3.068。
其中15号峰为青藤碱,16号峰为木兰花碱,17号峰为新绿原酸,21号峰为隐绿原酸,23号峰为绿原酸,26号峰为甘草苷,30号峰为异绿原酸B,32号峰为异绿原酸C,33号峰为哈巴俄苷,34号峰为藁本内酯,35号峰为甘草酸铵。
将15批金藤清痹颗粒HPLC指纹图谱导入药典委员会推荐的《中药色谱指纹图谱相似度评价系统2012版》软件分析,进行色谱峰匹配,确定35个共有峰为构成金藤清痹颗粒指纹图谱的特征峰,以23号绿原酸色谱峰为参照峰(S),样品共有峰的相对保留时间分别列于表2,15批金藤清痹颗粒共有峰的相对峰面积见表3。15批金藤清痹颗粒与标准指纹图谱相似度计算结果依次为0.939,0.988,0.994,0.994,0.996,0.990,0.990,0.989,0.987,0.992,0.995,0.984,0.996,0.994,0.994。
表2 15批金藤清痹颗粒共有峰的相对保留时间(tR)
表3 15批金藤清痹颗粒共有峰的相对峰面积(%)
2.5方法学考察
2.5.1精密度试验
取S1号样品,按照2.2项下方法制备供试品溶液,连续进样6次,记录其指纹图谱。以23号绿原酸峰为参照峰,计算出1-35号共有峰的相对保留时间RSD<0.85%,相对峰面积RSD<2.82%,表明仪器精密度良好。
2.5.2稳定性试验
取S1号样品,按照2.2项下方法制备供试品溶液,分别在0,3,6,9,12,18,24h进样,以23号绿原酸峰为参照峰,计算出1-35号共有峰的相对保留时间RSD<0.66%,相对峰面积RSD<2.97%,表明供试品溶液在24小时内稳定。
2.5.3重复性试验
取同一批号(S1号)样品,分别精密称取6份,按照2.2项下方法制备供试品溶液,分别进样,以23号绿原酸峰为参照峰,计算出1-35号共有峰的相对保留时间RSD<0.64%,相对峰面积RSD<2.77%,表明方法重复性良好。
以上所述仅是本发明的优选实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理及构思的前提下,还可以做出若干修饰和改进,这些也应属于本发明的保护范围。
Claims (8)
1.一种金藤清痹颗粒HPLC指纹图谱的建立方法,其特征在于,包括下列步骤:
1)供试品溶液的制备:取金藤清痹颗粒,研细,称取适量,置于具塞锥形瓶中,加入50%-90%甲醇,称定重量,超声提取20-50min,放冷至室温,用50%-90%甲醇补足减失的重量,摇匀,滤过,取续滤液,作为供试品溶液;
2)HPLC色谱条件的确定:Waters Xselect CSH C18柱,以乙腈-甲醇为流动相A、以0.05%-0.15%的甲酸水为流动相B,梯度洗脱;所述梯度洗脱条件为:
3)指纹图谱的制作:按步骤2)色谱条件对供试品溶液进行分析比较,得到由样品共有特征峰构成的金藤清痹颗粒HPLC标准指纹图谱。
2.如权利要求1所述的方法,其特征在于,步骤1)所述供试品溶液,按如下步骤制备:
取金藤清痹颗粒样品,研细,称取适量,置于具塞锥形瓶中,加70%甲醇适量,称定重量,超声提取30min,放冷至室温,用70%甲醇补足减失的重量,摇匀,滤过,取续滤液,得供试品溶液。
3.如权利要求1所述的方法,其特征在于,步骤2)所述流动相A为乙腈:甲醇=1:1,流动相B为0.1%甲酸水溶液。
4.如权利要求1所述的方法,其特征在于,所述色谱柱的规格为4.6×150mm,2.5μm。
5.如权利要求1所述的方法,其特征在于,步骤2)的色谱条件为检测波长:263nm;柱温:25℃;进样量:5μL。
6.如权利要求1所述的方法,其特征在于,所述金藤清痹颗粒HPLC标准指纹图谱,采用《中药色谱指纹图谱相似度评价系统2012版》软件进行相似度评价。
7.如权利要求1-6中任一项所述的方法,其特征在于,以绿原酸为参照峰,所述指纹图谱共有峰的相对保留时间tR依次分别为:0.048,0.050,0.052,0.068,0.080,0.089,0.095,0.106,0.111,0.115,0.164,0.183,0.221,0.292,0.378,0.739,0.757,0.805,0.840,0.874,0.935,0.965,1.000,1.083,1.203,1.506,1.573,1.635,1.816,1.987,2.026,2.277,2.496,2.928,3.068。
8.根据权利要求7所述的方法,其特征在于,所述标准指纹图谱有35个共有峰,其中15号峰为青藤碱,16号峰为木兰花碱,17号峰为新绿原酸,21号峰为隐绿原酸,23号峰为绿原酸,26号峰为甘草苷,30号峰为异绿原酸B,32号峰为异绿原酸C,33号峰为哈巴俄苷,34号峰为藁本内酯,35号峰为甘草酸铵。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311024413.9A CN117451865A (zh) | 2023-08-15 | 2023-08-15 | 金藤清痹颗粒指纹图谱的建立方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311024413.9A CN117451865A (zh) | 2023-08-15 | 2023-08-15 | 金藤清痹颗粒指纹图谱的建立方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117451865A true CN117451865A (zh) | 2024-01-26 |
Family
ID=89584282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311024413.9A Pending CN117451865A (zh) | 2023-08-15 | 2023-08-15 | 金藤清痹颗粒指纹图谱的建立方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117451865A (zh) |
-
2023
- 2023-08-15 CN CN202311024413.9A patent/CN117451865A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111337589A (zh) | 桔贝合剂hplc指纹图谱的建立方法 | |
CN113049724A (zh) | 桂枝芍药知母汤组合物的指纹图谱构建方法和检测方法 | |
CN111999423B (zh) | 一种颈痛颗粒指纹图谱的建立方法及其应用 | |
CN112444579B (zh) | 柴银口服液uplc指纹图谱的建立方法 | |
CN113514576A (zh) | 柴胡药材、提取物及单味制剂的指纹图谱的建立方法 | |
CN107688061A (zh) | 一种抗炎消毒胶囊的指纹图谱的构建方法 | |
CN107727754A (zh) | 一种小金制剂的hplc指纹图谱检测方法 | |
CN110297060A (zh) | 一种山苦荬药材指纹图谱检测方法及其指纹图谱 | |
CN117451865A (zh) | 金藤清痹颗粒指纹图谱的建立方法 | |
CN113341007A (zh) | 一种基于hplc特征图谱的枣仁安神胶囊全药味多成分含量测定方法 | |
CN112730647A (zh) | 一种昆仙胶囊中雷公藤甲素的鉴别及含量测定方法 | |
CN112557553A (zh) | 一种当归六黄汤组合物的指纹图谱构建方法和检测方法 | |
CN115754059B (zh) | 荆防制剂hplc指纹图谱的建立方法及其标准指纹图谱 | |
CN110857933B (zh) | 脉络舒通丸hplc指纹图谱的建立方法及其标准图谱 | |
CN102735785A (zh) | 一种中药组合物的气相色谱指纹图谱检测方法 | |
CN114910576B (zh) | 一种桂枝芍药知母汤中附子单酯型生物碱成分的检测方法 | |
CN114544833B (zh) | 鼻渊通窍颗粒多息药效预测特征图谱构建方法 | |
CN108845059B (zh) | 脉络舒通颗粒hplc指纹图谱的建立方法及其标准图谱 | |
CN101008632A (zh) | 五味子水煎液的hplc标准指纹图谱及其建立方法 | |
CN111562324B (zh) | 一种消乳散结胶囊多指标成分含量检测方法 | |
CN115267007A (zh) | 小儿感冒退热糖浆指纹图谱的建立方法及其指纹图谱 | |
CN119492811A (zh) | 一种金藤清痹颗粒多波长融合指纹图谱的建立方法 | |
CN102735766A (zh) | 杠板归药材指纹图谱的建立方法及其标准指纹图谱 | |
CN114487196B (zh) | 天麻眩晕宁颗粒hplc指纹图谱的建立方法及其指纹图谱 | |
CN110988156A (zh) | 鼻渊通窍颗粒hplc指纹图谱的建立方法及其标准图谱 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240724 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Applicant after: LUNAN PHARMACEUTICAL Group Corp. Country or region after: China Address before: 276006 No. 209 Hongqi Road, Shandong, Linyi Applicant before: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right |